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ORIGINAL ARTICLE
Genome-wide Peripheral Blood Leukocyte DNA Methylation
Microarrays Identified a Single Association with Inflammatory
Bowel Diseases
R. Alan Harris, PhD,1* Dorottya Nagy-Szakal, MD,2,3* Natalia Pedersen, MD,4* Antone Opekun, MS,2,5
Jiri Bronsky, MD,6 Pia Munkholm, MD, Dr. Med. Sci,4 Cathrine Jespersgaard, PhD,7 PaalSkytt Andersen, PhD,8
Bela Melegh, MD, PhD,9 George Ferry, MD,2 Tine Jess, M.D, Dr. Med. Sci,10 and Richard Kellermayer, MM, PhD2,3
Background: Crohn’s disease (CD) and ulcerative colitis (UC) are common forms of inflammatory bowel disease (IBD). Monozygotic (MZ)
twin discordance rates and epidemiologic data implicate that environmental changes and epigenetic factors may play a pathogenic role in IBD.
DNA methylation (the methylation of cytosines within CpG dinucleotides) is an epigenetic modification, which can respond to environmental
influences. We investigated whether DNA methylation might be connected with IBD in peripheral blood leukocyte (PBL) DNA by utilizing
genome-wide microarrays.
Methods: Two different high-throughput microarray-based methods for genome-wide DNA methylation analysis were employed. First, DNA
isolated from MZ twin pairs concordant (CD: 4; UC: 3) and discordant (CD: 4; UC: 7) for IBD was interrogated by a custom-made methylation-
specific amplification microarray (MSAM). Second, the recently developed Illumina Infinium HumanMethylation450 BeadChip arrays were used
on 48 samples of PBL DNA from discordant MZ twin pairs (CD: 3; UC: 3) and treatment-naive pediatric cases of IBD (CD: 14; UC: 8), as well
as controls (n ¼ 14). The microarrays were validated with bisulfite pyrosequencing.
Results: The MSAMs did not yield significant IBD associations. The Methylation BeadChip approach identified a single DNA methylation
association of IBD at TEPP (testis, prostate and placenta-expressed protein) when DNA isolated selectively from peripheral blood mononuclear
cells was analyzed (8.6% increase in methylation between CD and control, FDR ¼ 0.0065).
Conclusions: Microarray interrogation of IBD-dependent DNA methylation from PBLs appears to have limited ability to detect significant disease asso-
ciations. More detailed and/or selective approaches may be useful for the elucidation of connections between the DNA methylome and IBD in the future.
(Inflamm Bowel Dis 2012;18:2334–2341)
Key Words: inflammatory bowel disease, DNA methylation, peripheral blood, twin, TEPP
T he inflammatory bowel diseases (IBDs), includingCrohn’s disease (CD) and ulcerative colitis (UC), are
common human disorders with autoimmune characteristics
that affect more than four million people worldwide, about
a third of whom reside in the United States.1 The disorders
are associated with high morbidity, leading to a significant
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healthcare burden.2 The incidence of IBD peaks in young
adulthood and its prevalence is on the rise, especially in
the pediatric population.3–6 Recent observations implicate
that the increase in the number of pediatric patients with
IBD is a consequence of the overall amplified incidence
rather than a shift toward disease onset at younger age.7
Dietary and environmental factors of the industrialized
world have been proposed as etiologic culprits for these
shifting demographics by imposing critical changes during
prenatal and/or pediatric development in the key physio-
logic components of IBD pathogenesis.8–11
One group of molecular processes that has been
shown to dynamically respond to environmental/nutri-
tional influences is designated as epigenetic. Epigenetic
mechanisms mediate mitotically heritable changes in
gene expression that are not associated with DNA
sequence variation.12 The most stable epigenetic altera-
tion is the methylation of cytosines at CpG dinucleoti-
des (DNA methylation). This molecular modification at
gene promoters generally correlates with transcriptional
downregulation. DNA methylation is critical for devel-
opment and differentiation.13 It is catalyzed by DNA
methyltransferases and is ultimately dependent on die-
tary substrates and cofactors.14 Modification of the pre-
natal environment can shift levels of DNA methylation
at certain genomic loci and can associate with perma-
nent phenotype changes in insects15 and mammals as
well.16 Therefore, it has been proposed that epigenetic
changes, such as DNA methylation, may be an impor-
tant factor in the developmental origins of common
human diseases,17,18 including IBD.19 The high rate of
discordance for IBD within monozygotic (MZ) twin
pairs supports the possible role of epigenetic processes
in their etiologies.20,21 Discordant MZ twins have been
recognized to provide an opportunity for unraveling the
epigenetic aspects of disease etiology in autoimmune
diseases, such as systemic lupus erythematosus (SLE).22
Peripheral blood leukocyte (PBL) DNA samples from
MZ twins discordant and concordant for SLE have
been recently used successfully to identify DNA meth-
ylation associations of disease.23 Similar high-through-
put observations on PBL DNA methylation are lacking
in IBD.
In this study we set out to identify PBL DNA meth-
ylation associations of IBD by two independent methods of
genome-wide microarray interrogation. The study was
based on samples collected through the Danish Twin
Registry,24,25 the gene bank of the University of Pecs, Hun-
gary,26 the pediatric gastroenterology tissue bank of
Charles University, Prague, Czech Republic, and tissue
bank of the Pediatric Inflammatory Bowel Disease Consor-
tium Registry of the Baylor College of Medicine, Houston,
Texas.
MATERIALS AND METHODS
PBL DNA Samples
PBL DNA was isolated by different methodologies
depending on the tissue bank protocols at each site. The pre-
diction of this work was that uniform DNA methylation
changes associate with IBD, affecting each human cell lineage
equally. Therefore, we did not control for DNA isolation
methodology during our initial approach (see Results section
on TEPP).
Deidentified PBL DNA samples were obtained through
the Danish Twin Registry,24,25 the gene bank of the University
of Pecs, Hungary,26 the pediatric gastroenterology tissue bank
of Charles University, Prague, Czech Republic, and the Pedi-
atric Inflammatory Bowel Disease Consortium Registry of the
Baylor College of Medicine, which were established in agree-
ment with local and federal regulations. DNA isolation from
the twin samples was performed with the Maxwell 16 system
from Promega (Madison, WI) with the Blood DNA purifica-
tion kit. In order to increase the concentration of the extracted
DNA, Millipore microcon filters were used (http://www.milli-
pore.com/userguides/tech1/99394). PBL DNA at the Univer-
sity of Pecs was extracted with standard salting-out methods.
For the PBL DNA of the pediatric cohorts (used on the Illu-
mina arrays, other than the twins) either Gentra Puregene
(Qiagen, Valencia, CA) for whole blood DNA isolation was
used according to manufacturer’s recommendation on the sam-
ples from the Charles University, or the QuiAmp DNA mini
kit (Qiagen) was utilized on isolated peripheral blood mononu-
clear cells (PBMCs) from the cohort of the Baylor College of
Medicine. BD Vacutainer CPT Cell Preparation Tube with So-
dium Citrate was used in the latter case to isolate PBMCs
from PBL. Only age, gender, and disease status were collected
with the samples (except for the pediatric cohort, where phar-
macologic therapy was also recorded), the details of which are
shown in Table 1. Adult controls were healthy, free from any
chronic diseases. Pediatric controls included children who
underwent colonoscopic evaluation for diagnoses of hemato-
chezia, diarrhea, or abdominal pain, but whose endoscopy was
grossly and histologically normal.
Methylation Specific Amplification Microarray
(MSAM)
MSAM was carried out as previously described.18,27
MSAM is based on serial digestion of the DNA with methyla-
tion-sensitive and insensitive restriction endonuclease iso-
chizomers: SmaI and XmaI, respectively. The endonuclease
digestion is followed by polymerase chain reaction (PCR)-
mediated amplification and processing toward differentially la-
beled microarray hybridization (cohybridization) to compare
the relative difference in DNA methylation between two sam-
ples at a large number of SmaI/XmaI genomic intervals. Eight-
een independent MZ twin–twin cohybridizations (see Table 1)
were performed. We designed a custom microarray (Agilent
Technologies, Santa Clara, CA). SmaI/XmaI intervals between
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100–2000 bp, along with negative control intervals in the
range 10–15 kbp, were identified based on the human genome
assembly (NCBI36/UCSC hg18) excluding chromosome X
and Y. Intervals containing single nucleotide polymorphisms,
based on dbSNP 129 (http://www.ncbi.nlm.nih.gov/projects/
SNP/), which disrupted or introduced SmaI/XmaI cut sites were
removed from consideration. The intervals were uploaded to
Agilent eArray (https://earray.chem.agilent.com/earray/) in
order to identify high-density probes contained within the inter-
vals. eArray filtering for probes in known copy number varia-
tion regions was also applied. The final array design consisted
of 99,071 probes interrogating 41,079 (100–2000 bp length)
intervals and 100 probes interrogating 10–15 kbp negative con-
trols in addition to the standard Agilent array controls. There-
fore, the custom array covered 45.31% (41,079 out of 90,657
in the human genome) of the potentially informative 100–2000
bp SmaI/XmaI intervals. To exclude falsely significant findings
arising from the massive numbers of loci interrogated, multiple
testing correction of the P-values was performed using Benja-
mini and Hochberg’s method28 (false discovery rate: FDR).
Based on our previous experience,18 we first examined inter-
group differences exceeding 1.8-fold with P < 0.0002 for sig-
nificant association. A secondary criteria of significance was
determined at FDR < 0.5 at intervals where intergroup differ-
ences at select SmaI/XmaI intervals were >1.2-fold.
Infinium Methylation Assay Microarrays
In all, 48 PBL DNA (3 MZ twin discordant for CD, 3
MZ twin discordant for UC; and pediatric samples: 14 control,
14 CD and 8 UC collected at the time of diagnostic endos-
copy in untreated patients) samples following quality control
with PicoGreen (http://probes.invitrogen.com/media/pis/
mp07581.pdf) were processed by Infinium HumanMethyla-
tion450 BeadChip Kits (Illumina San Diego, CA; http://
www.illumina.com/products/methylation_450_beadchip_kit-
s.ilmn) according to the manufacturer’s recommendations
through automated processes in the Core Laboratory for
Translational Genomics of the Baylor College of Medicine.
Arrays were imaged with BeadArray Reader using standard
recommended Illumina scanner settings. GenomeStudio soft-
ware v. 2010.3.0.30128 was used to generate beta values nor-
malized to internal control probes. Internal controls deter-
mined the array processing to be of good quality. Only the
482,421 CpG probes on the array were used for subsequent
analysis. The R LIMMA package29 was employed to compare
beta values between normal controls and CD or UC affected
individuals. Limma fitted a linear model to beta values for
each probe in the compared samples and then calculated t-sta-
tistic using an empirical Bayesian model that moderates the
standard errors across probes. P-values were calculated from
the moderated t-statistics and FDR was determined to identify
differentially methylated probes. The criterion for significant
association was set at FDR < 0.2. The raw data of the microar-
rays was uploaded to Gene Expression Omnibus (GEO; Series
GSE32148) and is accessible at: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token¼pjszvekkmmaeyzu&acc¼GSE32148.
Bisulfite Pyrosequencing
Analytical validation using the same cohort as the array
studies was performed by bisulfite pyrosequencing at select
TABLE 1. Summary of PBL DNA Samples
Cohorts Diagnosis
Age (years)
Gender
Mean Median Min to Max (M/F)
Danish twin registry (n¼number
of twin pairs)
CD discordant (n¼4) 44.75 43.5 43–49 2/2
UC discordant (n¼7) 45.71 49 33–56 2/5
CD concordant (n¼4) 46.5 46 44–50 2/2
UC concordant (n¼3) 41 43 36–44 0/3
Hungarian cohort C-CD 36.85 37 24–52 10/10
(n¼80) C-UC 37.6 37.5 22–56 10/10
CD 36.85 37 24–52 10/10
UC 36.85 37 24–52 10/10
Illumina cohort H 12.14 13.25 3.5–17.5 6/8
(n¼36) CD 14.43 15.5 9–17 8/6
UC 12.88 13.5 9–17 5/3
BCM - Crohn’s disease cohort
(PBMC DNA)
H 11.94 13 0.1–17.5 6/15
(n¼55) CD new 14.50 15.05 9–18 13/11
CD Rx 14.55 14.9 9–18 4/6
BCM, Baylor College of Medicine; PBMC, peripheral blood mononuclear cell. C, healthy control; H, control where no intestinal inflammation was detected.
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loci. This analysis was followed by validation of differential
methylation status using expanded or independent cohorts (see
PBL DNA Samples paragraph above). PBL DNA was bisulfite
converted with EZ DNA Methylation-Gold Kit (D5006, Zymo
Research, Orange, CA). DNA was amplified with traditional
PCR methodology following bisulfite conversion and including
a biotinylated primer in the sets (Supporting Table 1). A quan-
titative bisulfite pyrosequencing protocol was used for all
methylation analyses with the utilization of the Pyro Q CpG
program (Qiagen, Hilden, Germany). Methylation measure-
ments at (ANO1-associated SmaI/XmaI: chr11:69597807-
69598085, EHD1-associated SmaI/XmaI: chr11:64377161-
64377539) or in the vicinity (MGRN1-associated SmaI/XmaI:
chr16:4654296-4655675) of both of the SmaI/XmaI sites of
the gene-associated intervals were performed in the case of
the validation measurements of the MSAMs. An algorithm
was used to calculate and compare methylation ratios at these
intervals.27 Illumina array validation was performed at three
candidate loci: FAM53B-associated CpG site (chr10:126360669-
126360669); SLC6A9-associated CpG site (chr1:44466601-
44466601); TEPP-associated CpG site (chr16: 58019367-
58020365). Only the results of assays that passed quality con-
trol were used. The criterion for significant association for
bisulfite pyrosequencing results was P < 0.05 with nonpara-
metric U-test. The primer sequences for the bisulfite pyrose-
quencing measurements are described in Supporting Table 1.
Statistical Analyses
Statistical analysis of the Illumina arrays is described
above. Pearson’s correlation analysis was used in the correla-
tion studies. The nonparametric Mann–Whitney U-test was
employed in the intergroup comparisons. Significance was set
at P < 0.05.
RESULTS
MSAM in Discordant MZ Twins Found No Signifi-
cant IBD Association
None of the discordant MZ twin comparisons yielded
average disease to healthy ratio comparisons that met our
criteria of significance (see Materials and Methods). Never-
theless, we wished to test whether relaxing the selection
criteria may still provide significant findings. The selection
criteria were relaxed by different approaches and top candi-
dates were selected for bisulfite pyrosequencing. MRGN1
showed over 1.4 average fold difference between disease
and healthy (P < 0.05); ANO1 showed two out of four
comparisons exceeding 1.95-fold difference between dis-
ease and healthy; and EHD1 showed three out of four com-
parisons exceeding 1.5-fold difference between disease and
healthy. Pyrosequencing failed to confirm the significant
DNA methylation differences between MZ twins discordant
for IBD indicated by the arrays (correlation at MGRN: r ¼
0.28, P ¼ 0.72, at ANO1: r ¼ 0.68, P ¼ 0.32; and at
EHD1: r ¼ 0.3, P ¼ 0.7, respectively). Therefore, MSAM
did not yield significant results.
With the assumption that disease-specific epigenetic
differences between MZ twins may be suppressed,30 and
the MSAM might have been more sensitive than our vali-
dation method, we measured the methylation of candidate
loci in an independent cohort of adults with IBD and
healthy controls. None of our measurements showed dis-
ease-specific DNA methylation in the PBL DNA samples
from this independent cohort (see Supporting Fig. 1 as an
example).
Infinium Methylation Assay Microarrays Did Not
Show Significant IBD Association
We first examined the genetically unrelated pediatric
samples on the Illumina arrays. After correcting for multi-
ple testing, none of the CD to control comparisons was sig-
nificant (FDR > 0.2 for all). Similar relaxation of the FDR
was done with success when assessing PBL DNA methyla-
tion associations of SLE.23
We found a total of six CpG sites in the human ge-
nome, where UC to control comparisons resulted in over
4% mean methylation difference (this value approaches the
reliability of the bisulfite pyrosequencing validation
method19) with FDR < 0.2 (Table 2) in the pediatric
groups of the Illumina arrays. Bisulfite pyrosequencing val-
idation at select loci from this UC-specific group gave
excellent correlation with the microarrays (Fig. 1). How-
ever, group comparisons between UC and control were not
significant (Supporting Fig. 2). This latter finding is likely
the result of the low (less than 15% difference in five out
of the six candidates) intergroup methylation differences
FIGURE 1. Scatterplot of methylation levels obtained by Infinium
HumanMethylation450 Microarrays (Microarray) versus bisulfite
pyrosequencing at the SCL6A9, FAM53B, and TEPP-associated CpG
sites. Significant correlation was observed. r ¼ 0.963; P <
<0.00001.
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detected by the microarrays in addition to relatively large
intragroup variation that was predicted by the overall high
FDRs.
Selective PBMC DNA Analysis Identifies TEPP CpG
Methylation Association with IBD
The DNA samples of this study originated from dif-
ferent tissue banks utilizing various extraction methods. To
address the possibility that the sample variation originating
from technical and geographic disparity masked disease-
specific DNA methylation, we performed a selective bioin-
formatic analysis of the samples from the Baylor College
of Medicine cohort. In this case, the DNA was extracted
from PBMCs excluding neutrophil granulocytes with uni-
form methodology. This analysis showed a single CD-spe-
cific DNA methylation change associated with TEPP with
FDR < 0.2 (chr16:58019866-58019866, CD-C average
methylation difference: 8.6%; FDR ¼ 0.0065). Bisulfite
pyrosequencing validated the results (included in Fig. 1)
and showed a significant (P ¼ 0.011) CD-associated
increase in methylation at this locus. However, this
increase was not specific to CD, but was present in
untreated UC patients as well (P ¼ 0.013; Fig. 2A). When
the control and treatment-naı¨ve CD groups were expanded,
CpG methylation at this locus showed an even more signif-
icant association with CD (P < 0.0001; Fig. 2B). In the
meantime, the amplified DNA methylation in treatment-
naı¨ve CD was absent in treated children (Fig. 2C).
DISCUSSION
Identification of disease-specific epigenetic (including
DNA methylation) changes is a very extensive area of cur-
rent biomedical research. Epigenetic associations could
support the unraveling of disease etiology, provide novel
biomarkers, and aid the development of potential preventa-
tive and/or therapeutic measures for disorders such as
IBD.31,32 Based on MZ twin discordance rates, the relative
genetic contribution to CD and UC is low,33 supporting the
importance of nongenetic (including epigenetic and/or other
molecular processes within the large biological components
of gastrointestinal disease10) processes in their etiology, as
discussed in the introduction.
Peripheral blood (PB) is the most commonly obtained
and stored biological specimen and PBL DNA constitutes
the vast majority of gene bank samples. Therefore, identifi-
cation of disease-specific molecular characteristics from PB
or PBL is highly feasible. Recent findings indicate that PB
microRNAs (small RNA molecules modulating gene
expression through epigenetic mechanisms) may serve as
useful biomarkers of CD.36
In case a DNA methylation modification at a disease
susceptibility locus occurs before gastrulation, it can be
detected in all tissues of the body, as has been observed at
metastable epialleles in mice.16 Therefore, if such loci exist
in humans for certain diseases, then the disease-specific
DNA methylation change could be detected from any type
of cell, including leukocytes obtained from PB specimens.
Our approach to DNA methylation associations of IBD in
PBL DNA was based on this prediction.
We first used the MSAM technique on MZ twin sam-
ples, but could not identify any significant IBD association.
These results indicated that either the MZ twin-based
approach or our MSAM technique is insufficient to identify
IBD-specific DNA methylation from PBL DNA, or that
uniform epigenetic changes may not exist in association
with the disease group in peripheral white blood cells. One
limitation of the MSAM technique is that it does not pro-
vide information on the actual levels of DNA methylation,
just the relative difference in methylation between two dif-
ferent (disease-healthy, for example) samples at the same
genomic region (SmaI/XmaI interval in this case). There-
fore, at genomic loci where DNA methylation is low, even
subtle changes may show up as highly significant (for
example, 1% methylation in healthy individuals and 3%
methylation in disease would result in a 3-fold difference
on the array). Subtle methylation differences are of ques-
tionable physiologic relevance and are very difficult to val-
idate with sequencing methodologies. Therefore, we turned
TABLE 2. Genomic Loci
Coordinates Associated Gene C UC UC-C FDR
chr13:20771319-20771319 56.19 27.33 28.86 0.07
chr20:60915009-60915009 LAMA5 65.17 51.74 13.43 0.16
chr6:31803832-31803832 C6orf48,SNORD52 41.81 46.46 4.65 0.08
chr2:34719565-34719565 68.06 73.05 4.99 0.19
chr1:44466601-44466601 SLC6A9 75.83 81.34 5.51 0.16
chr10:126360669-126360669 FAM53B 42.40 55.00 12.60 0.07
Coordinates of UC-associated CpG candidates where disease-specific DNA methylation occurred according to the Illumina arrays from the pediatric cohort
(loci meeting criteria for >4% mean methylation difference between UC and control: C; and Benjamini-Hochberg FDR < 0.2). Numbers represent percent
methylation. Gene associations are based on the Infinium HumanMethylation450 v1.1 manifest supplied by Illumina.
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to the Infinum methylation assay based Infinium Human-
Methylation450 BeadChip Kits.
Secondary to our negative findings with the MSAM
approach in the twin cohort, only a subset of MZ twins
discordant for CD and UC were examined by the Illumina
arrays. One reason for this approach was the prediction
based on healthy twin observations37 that a twin with a dis-
ease in discordant MZ pairs may be epigenetically less dif-
ferent from the healthy twin sibling at critical pathogenic
loci, as compared to unrelated healthy individuals. How-
ever, at least according to one publication, SLE-associated
DNA methylation was not influenced by relatedness (i.e.,
disease-specific DNA methylation difference was as high
between unrelated patients and controls, as between
affected twins and healthy counterparts in MZ twin pairs).
Nevertheless, we decided to first study unrelated individu-
als with IBD where epigenetic differences could be higher
than in MZ twins. Therefore, PBL DNA samples collected
at diagnosis from untreated pediatric cases of IBD were
tested and compared to controls. The untreated pediatric
cases eliminated the possible confounding factor of thera-
peutic interventions inducing nonspecific DNA methylation
changes.38 However, because the patients were unrelated
their comparisons carried the potential for genetic varia-
tion-induced DNA methylation differences being identified.
Therefore, our plan was to overlap candidate loci deter-
mined in the pediatric cohort with loci identified through
the discordant MZ twin comparisons.
We could not identify IBD-specific PBL DNA meth-
ylation association in unrelated children where even IBD-
linked genetic variation induced DNA methylation
changes could have been present. Consequently, we did
not proceed with overlapping the pediatric cohort results
with the independent adult MZ twin samples on the Illu-
mina arrays.
Studies with high-throughput methodologies applied
on clinical samples frequently bare limitations. Some of
the confounding factors of our analyses may have been:
the low power secondary to small sample sizes, the limited
coverage and/or resolution of the microarrays employed,
and the clinical heterogeneity of both the control and IBD
groups (nonhealthy control children, healthy adults, twins,
adult treated IBD patients likely with different disease sub-
types) studied. However, as stated earlier, the original hy-
pothesis of our work was that uniform DNA methylation
changes may exist in humans, which predispose to the de-
velopment of IBD independently from disease subtypes
within CD and UC.
Our largely negative findings with MSAMs and
Infinum Methylation Assays implicate that microarray
profiling of DNA methylation from PBL is less likely to
yield positive results in IBD. Subfractionation of PBL into
lymphocyte subsets and performing microarray compari-
sons with such DNA samples may be valuable in the future
since DNA methylation is cell type-specific. The one posi-
tive IBD association at TEPP when PBMCs were selec-
tively analyzed would support this conclusion. Indeed,
FIGURE 2. Methylation levels at the TEPP-associated CpG site in
the select pediatric PBMC cohort of the study (see Table 2). (A)
Bisulfite pyrosequencing results from the PBMC samples of the
Infinium HumanMethylation450 Microarrays. The significant
increase in methylation was confirmed by bisulfite pyrosequencing
in the CD and UC cohorts compared to controls (n ¼ 6–14). (B)
Extension of the measurements to larger groups of PBMC DNA
from controls and treatment-naı¨ve CD patients further supported
the validity of our findings (n ¼ 19–22). (C) The increased level of
methylation in treatment-naı¨ve (CD) patients was lost when com-
pared to CD patients receiving therapy (CD-rx; three biologic
monotherapy; two biologicþimmunomodulator, two mesalamine
alone, one steroid alone, one immunomodulator alone, one ster-
oidþimmunomodulator) (n ¼ 10–22).
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interferon-gamma (IFNG) methylation in isolated periph-
eral T cells correlated with IBD, for example.39 However,
IFNG methylation difference between IBD and controls
was less than 4% in this case, which would have been
likely missed by the resolution of the currently available
high-throughput interrogation methods.
TEPP encodes for testis, prostate, and placenta-
expressed protein with uncertain function.40 It is poorly
expressed in bone marrow, whole blood, thymus, mono-
cytes, and T-cell subsets, as well as in the appendix
(expression atlas 2 data from U133A and GNF1H chips),
implicating that the physiologic relevance of the small av-
erage DNA methylation increase (from 83% in controls to
94% in CD, Fig. 2A) detected from PBMCs is question-
able. Furthermore, the CD dependent methylation increase
was lost in treated patients. One explanation for this finding
is that PBMC subset modifications (altered ratios of macro-
phages, T- and B-cell subsets, etc., with differing TEPP
methylation levels) characteristic for IBD at onset are lost
upon treatment. However, there are no flow cytometric
data available for our patients, which could specifically
address this prediction. Nevertheless, we can conclude that
IBD-associated DNA methylation increase in PBMC DNA
at TEPP, a gene poorly expressed in peripheral blood leu-
kocytes, is small and is not disease-specific. Additionally,
only treatment-naı¨ve patients showed this difference.
Therefore, the functional relevance and the potential diag-
nostic value of this finding appear limited.
Numerous observations on links between gene and
cell type-specific DNA methylation and IBD have been
made, where either the low fraction of the specific cell
type (regulatory T cells, for example41) or the unique loca-
tion of the DNA methylation correlate (such as in the inter-
leukin 17A: IL17A42) provide limitations to detectability
from PBL DNA by microarray methodology. Increasing
the depth of interrogation with methods such as genome-
wide direct sequencing43 may increase the chances of
determining DNA methylation associations of IBD in PBL,
and PBL subtypes. Unfortunately, the financial aspects of
such interrogation in reliable sample sizes provide signifi-
cant constraints to such studies currently.
Intestinal biopsies may offer more readily identifiable
DNA methylation correlates of IBD through genome-wide
microarray analysis. Both targeted gene methylation44 and
DNA methylation microarray45 assessments have detected
numerous colonic mucosal associates of inflammation in
IBD. Techniques with higher resolution may offer even
more insight into the intestinal mucosal DNA methylation
aspects of the disease group.
In summary, our largely negative study can signifi-
cantly guide epigenetic investigations in IBD regarding
technical planning and tissue selection. Our findings on
TEPP-associated DNA methylation may also prove of sig-
nificance in the future.
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